000			01932 a2200505 4500
005			20250514230838.0
264		0	_c20050728
008			200507s 0 0 eng d
022			_a0008-5472
024	7		_a10.1158/0008-5472.CAN-04-3701 _2doi
040			_aNLM _beng _cNLM
100	1		_aLashinger, Laura M
245	0	0	_aBortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. _h[electronic resource]
260			_bCancer research _cJun 2005
300			_a4902-8 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aApoptosis Regulatory Proteins
650	0	4	_aBoronic Acids _xpharmacology
650	0	4	_aBortezomib
650	0	4	_aCaspase 3
650	0	4	_aCaspase 8
650	0	4	_aCaspases _xmetabolism
650	0	4	_aCell Cycle Proteins _xmetabolism
650	0	4	_aCell Line, Tumor
650	0	4	_aCyclin-Dependent Kinase Inhibitor p21
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aDrug Synergism
650	0	4	_aEnzyme Activation _xdrug effects
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMembrane Glycoproteins _xpharmacology
650	0	4	_aProstatic Neoplasms _xdrug therapy
650	0	4	_aPyrazines _xpharmacology
650	0	4	_aTNF-Related Apoptosis-Inducing Ligand
650	0	4	_aTumor Necrosis Factor-alpha _xpharmacology
650	0	4	_aUrinary Bladder Neoplasms _xdrug therapy
700	1		_aZhu, Keyi
700	1		_aWilliams, Simon A
700	1		_aShrader, Marissa
700	1		_aDinney, Colin P N
700	1		_aMcConkey, David J
773	0		_tCancer research _gvol. 65 _gno. 11 _gp. 4902-8
856	4	0	_uhttps://doi.org/10.1158/0008-5472.CAN-04-3701 _zAvailable from publisher's website
999			_c15591061 _d15591061